Hua Qingling, Zhu Yanzhe, Liu Hu, Ye Xiaobing
Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 West Zheshan Road, Wuhu, 241001, China.
Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Int Urol Nephrol. 2016 Sep;48(9):1437-43. doi: 10.1007/s11255-016-1316-x. Epub 2016 May 11.
Biochemical recurrence (BCR), or an elevation in prostate-specific antigen in men after treatment for localized prostate cancer, is an early indication of clinical progression, distant metastases, and mortality. Correlations have also recently been established between diabetes and the incidence and mortality of prostate cancer. However, it remains unknown whether diabetes may predict BCR.
We performed a meta-analysis of published articles to investigate the prognostic value of diabetes for BCR in prostate cancer. Eight studies and 11,923 patients were included in our meta-analysis. The relative risk (RR) and its 95 % confidence interval (CI) were calculated.
We found no apparent association between diabetes and BCR (adjusted RR 1.04; 95 % CI 0.87-1.22).
The evidence of this meta-analysis indicates that diabetes is not a predictor of risk of BCR in patients with prostate cancer.
生化复发（BCR），即局限性前列腺癌患者治疗后前列腺特异性抗原升高，是临床进展、远处转移和死亡的早期指标。最近也已确定糖尿病与前列腺癌的发病率和死亡率之间存在关联。然而，糖尿病是否可预测生化复发仍不清楚。
我们对已发表的文章进行了荟萃分析，以研究糖尿病对前列腺癌生化复发的预后价值。我们的荟萃分析纳入了8项研究和11923例患者。计算相对风险（RR）及其95%置信区间（CI）。
我们发现糖尿病与生化复发之间无明显关联（校正RR 1.04；95%CI 0.87 - 1.22）。
这项荟萃分析的证据表明，糖尿病不是前列腺癌患者生化复发风险的预测因素。
